(4S,5R)-4-methyl-5-phenyl-3-acetyl-2-oxazolidinone | 192822-87-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4S,5R)-4-methyl-5-phenyl-3-acetyl-2-oxazolidinone
• 英文别名: 3-acetyl-(4S,5R)-4-methyl-5-phenyl-2-oxazolidinone；(4S,5R)-3-acetyl-4-methyl-5-phenyloxazolidin-2-one；(4S,5R)-3-Acetyl-4-methyl-5-phenyl-2-oxazolidinone；N-Acetyl-(4S,5R)-4-methyl5-phenyl-2-oxazolidinone；(4S,5R)-3-acetyl-4-methyl-5-phenyl-1,3-oxazolidin-2-one
• CAS: 192822-87-0
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: GCCVRCZMVYRDCO-KWQFWETISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4S,5R)-4-methyl-5-phenyl-3-acetyl-2-oxazolidinone 在 palladium 10% on activated carbon 氢气 作用下， 以 甲醇 、 乙醇 为溶剂， 以98%的产率得到N-acetyl amphetamine
  参考文献：
  名称：

  METHOD FOR MAKING PHARMACEUTICAL COMPOUNDS

  摘要：

  制备B式苯乙胺的方法：其中R2、R3、R4、R5、R6、Rα、Rβ和Rn分别独立地选自氢、烷基、酰基、芳基、酰胺、氨基酸、糖和核苷酸。该方法包括在无碱的情况下还原A式化合物的步骤：其中R2、R3、R4、R5、R6、Rα、Rβ和Rn如上所定义。

  公开号：

  US20100125146A1

文献信息

• 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20050113429A1

  公开（公告）日：2005-05-26

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2b , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了通式(I)中的新6-烯基-和6-炔基-epothilone衍生物，其中R1a、R1b、R2b、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z具有说明中指示的含义。这些新化合物通过稳定形成的微管蛋白质与微管结合。它们能够以特定阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或状况。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病的治疗（如牛皮癣、关节炎）。还描述了这些化合物的使用方法和制备方法。
• 6-Alkenyl -, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
  申请人：Klar Ulrich

  公开号：US20060046997A1

  公开（公告）日：2006-03-02

  This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R 1a , R 1b , R 2a , R 3a , R 3b , R 4 , R 5 , R 6 , R 7 , A, Y, D, E, G, Y and Z have the meanings that are indicated in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and thus find use in treating diseases or conditions associated with the need for cell growth, division and/or proliferation. Thus the compounds are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (such as psoriasis, arthritis). Methods of use and preparation of the compounds are also described.

  该发明描述了新的6-烯基和6-炔基-依托酮衍生物，其一般式为（I），其中R1a、R1b、R2a、R3a、R3b、R4、R5、R6、R7、A、Y、D、E、G、Y和Z的含义如描述中所示。这些新化合物通过稳定形成的微管蛋白质与微管相互作用。它们能够以特定于阶段的方式影响细胞分裂，因此可用于治疗与细胞生长、分裂和/或增殖需求相关的疾病或症状。因此，这些化合物适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺癌、乳腺癌、肺癌、头颈癌、恶性黑色素瘤、急性淋巴细胞白血病和骨髓性白血病。此外，它们也适用于抗血管生成治疗以及慢性炎症性疾病（如牛皮癣、关节炎）的治疗。该文还描述了这些化合物的使用方法和制备方法。
• Practical Formal Total Syntheses of the Homocamptothecin Derivative and Anticancer Agent Diflomotecan via Asymmetric Acetate Aldol Additions to Pyridine Ketone Substrates
  作者：René Peters、Martin Althaus、Christian Diolez、Alain Rolland、Eric Manginot、Marc Veyrat

  DOI：10.1021/jo060928v

  日期：2006.9.1

  scalable asymmetric routes to DE ring fragment 7, a key building block in the synthesis of the homocamptothecin derivative diflomotecan 4, are described. The “acetal route” starts from 2-chloro-4-cyanopyridine 8 and represents an enantioselective and optimized modification of the original racemic discovery chemistry synthesis. The inefficient optical resolution procedure was replaced by an efficient asymmetric

  描述了两种实际，有效且可扩展的至DE环片段7的不对称路线，DE环片段7是高喜树碱衍生物双氟醚4合成中的关键组成部分。“缩醛途径”始于2-氯-4-氰基吡啶8，代表对映体选择性和对原始外消旋发现化学合成的优化修饰。低效率的光学拆分程序被高效的不对称乙酸酯醛醇加成剂（dr 87:13）取代到酮基质上，这是生成具有高立体选择性的（R）-构型四元立体中心的关键步骤。7最终，在九个步骤中以8.9％的总收率（er 99.95：0.05）获得了目标产物，从而避免了色谱纯化，并且与初始操作相比具有优势。在从2-氯异烟酸酸41开始的相关“酰胺途径”中，使用仲酰胺指导基团来促进吡啶3-位的邻位锂化。该方案的关键步骤再次包括实际的不对称乙酸羟醛加成（dr = 87:13）。因此，在九个步骤中，仅需进行一次色谱纯化，即可以11.1％的总收率（er> 99.95：0.05）获得DE环结构单元7。
• 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use
  申请人：Schering AG

  公开号：US20040014978A1

  公开（公告）日：2004-01-22

  The invention relates to novel epothilone derivatives of general formula (I), wherein R8 means a halogen atom, especially a fluorine or chlorine atom, and the remaining substituents have the meanings given in the description. The novel compounds are suitable for producing medicaments.

  本发明涉及一种新的环丙沙星衍生物，其一般式为（I），其中R8表示卤素原子，特别是氟或氯原子，其余取代基的含义如说明书所述。这种新化合物适用于制备药物。
• 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use
  申请人：Klar Ulrich

  公开号：US20050187270A1

  公开（公告）日：2005-08-25

  A compound of formula C, BC and ABC.

  一个化学式为C、BC和ABC的化合物。